12/23
04:01 pm
vor
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
Medium
Report
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
12/19
11:38 am
vor
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at JPMorgan Chase & Co. from $43.00 to $40.00. They now have an "overweight" rating on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at JPMorgan Chase & Co. from $43.00 to $40.00. They now have an "overweight" rating on the stock.
12/17
10:22 am
vor
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
12/15
08:00 am
vor
Vor Bio Announces $150 Million Private Placement
Medium
Report
Vor Bio Announces $150 Million Private Placement
12/10
11:24 am
vor
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]
Low
Report
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]
12/9
08:07 am
vor
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $43.00 price target on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $43.00 price target on the stock.
11/25
09:06 am
vor
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
Medium
Report
Vor Biopharma (NASDAQ:VOR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $9.00 price target on the stock.
11/14
08:09 am
vor
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at HC Wainwright from $55.00 to $32.00. They now have a "buy" rating on the stock.
11/13
07:23 am
vor
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
11/10
09:56 pm
vor
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
High
Report
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
11/10
04:01 pm
vor
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
High
Report
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
11/8
11:45 am
vor
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
Low
Report
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
11/7
08:00 am
vor
Vor Bio to Participate in Upcoming Investor Conferences
Low
Report
Vor Bio to Participate in Upcoming Investor Conferences
11/3
08:00 am
vor
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
Medium
Report
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
10/31
04:30 pm
vor
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/29
01:47 pm
vor
Vor Biopharma (NASDAQ:VOR) had its price target raised by analysts at HC Wainwright from $3.00 to $52.00. They now have a "buy" rating on the stock.
Low
Report
Vor Biopharma (NASDAQ:VOR) had its price target raised by analysts at HC Wainwright from $3.00 to $52.00. They now have a "buy" rating on the stock.
10/29
11:01 am
vor
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Low
Report
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
10/22
04:30 pm
vor
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
Medium
Report
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
10/17
08:00 am
vor
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
Low
Report
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
10/16
08:00 am
vor
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
Medium
Report
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
10/16
06:39 am
vor
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Baird R W from a "hold" rating to a "strong-buy" rating.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Baird R W from a "hold" rating to a "strong-buy" rating.
10/15
08:12 am
vor
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $64.00 price target on the stock, up previously from $20.00.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $64.00 price target on the stock, up previously from $20.00.
10/15
07:11 am
vor
Vor Biopharma (NASDAQ:VOR) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Vor Biopharma (NASDAQ:VOR) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
10/14
08:00 am
vor
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
Medium
Report
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
10/3
04:53 pm
vor
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]